Reference Standards Improve AAV Production

Hits:40   Date: 1/13/2026

Amsbio announces a new range of well characterized Adeno-Associated Virus (AAV) reference standards that enable researchers to significantly improve their AAV production processes.

Adeno-associated virus can be engineered to transport DNA of interest to target cells, without any viral genes - making them a highly desirable and safe tool for gene therapy. However, one of the greatest challenges in AAV production is that AAV preparations contain a considerable number of viral particles without gene payloads. Even after purification procedures, samples include empty capsids. In gene therapy applications, the reliability and accuracy of research depend significantly on the use of high-quality reference materials.

AAV reference standards – a safe strategy for effective gene therapy

The highly characterised and well-defined reference standards available from Amsbio are essential for quantitative AAV production. These thoroughly analyzed particles offer precise titers and well-defined full-to-empty capsid ratios. Their comprehensive characterization is vital for standardizing measurements, ensuring consistency across experiments, and providing reliable data for gene therapy applications and other research involving AAV vectors.

Amsbio offers two types of AAV reference materials – full and empty for a wide range of serotypes. Full AAV reference standards are essential, well-characterized materials used in gene therapy to calibrate qPCR and ELISA assays, ensure consistency across labs, validate testing methods, and establish benchmarks for critical quality attributes (CQAs). Their use helps to guarantee the safety, quality, and comparability of AAV gene therapy products from research to clinical use, particularly for determining vector genome concentration and the full-to-empty capsid ratio.

Empty AAV reference standards are crucial for gene therapy development and manufacturing, serving as benchmarks to quantify the percentage of "full" versus "empty" viral capsids in production batches. Their use helps ensure product quality, safety, and consistency by calibrating analytical methods like qPCR, HPLC, and ELISA, and assessment of immunogenicity and biodistribution.

Each AAV reference standard supplied by Amsbio undergoes extensive characterization, including ddPCR, ELISA, silver staining, mass photometry, and full safety testing for bioburden, mycoplasma, and endotoxin. The reported quantification data for each AAV reference standard is traceable to ATCC Reference Standard Material, providing confidence and consistency for gene therapy development, QC, and regulatory workflows.

For further information please visit https://www.amsbio.com/aav-reference-standards/ or contact Amsbio on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.

Amsbio, part of the Europa Biosite group, is a leading life sciences company supporting drug discovery, translational research, and cell and gene therapy across Europe, North America, and wider international markets. With in depth expertise in advanced cell culture, 3D cell models, and cryopreservation, Amsbio is well placed to help researchers progress from early discovery through to clinical and GMP-ready applications. The company’s portfolio of innovative products and services supports multiple stages of the research pipeline, spanning target discovery, assay development, and disease modelling, through to stem cell and organoid-based research. Key solutions include the integrated stem call platform combining StemFit™ media, iMatrix™ recombinant laminins, and CELLBANKER™ cryopreservation technology, alongside extracellular matrix technologies, biospecimens, glycobiology tools, kits and assays, and a wide range of custom services including viral delivery.

Drawing on extensive GMP expertise and a comprehensive human and animal biorepository, Amsbio is internationally recognized for delivering high-quality, application-ready products and services. Amsbio has a consistent record of close scientific collaboration with partners in academic, biotech, and pharmaceutical markets to translate innovation from bench to bedside.

---------------------

Worldwide HQ

AMS Biotechnology Europe Ltd (Amsbio)
2-3, Munro House
Trafalgar Way
Bar Hill
Cambridge, CB23 8SQ
UK
Tel: +44-1235-828200
Fax: +44-1235-820482
Email: info@amsbio.com
Web www.amsbio.com
 
North American HQ
 
Amsbio LLC
1035 Cambridge Street
Cambridge
MA 02141
USA
Tel: +1.617.945.5033
Tel: +1.800.987.0985 (toll free)
Email: info@amsbio.com
Web www.amsbio.com